Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Apr;41(4):609–617. doi: 10.1038/bjc.1980.104

Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus.

B M von Blomberg, J Glerum, J J Croles, J Stam, H A Drexhage
PMCID: PMC2010289  PMID: 7387858

Abstract

The effects are reported of a combination therapy of i.v. C. parvum and cyclophosphamide on the survival time and immune responses of patients with inoperable squamous-cell carcinoma of the bronchus. The immune status of the patients was evaluated by determining the antibody response to C. parvum, the E and EAC rosettes, the PHA response of blood lymphocytes, the skin-test reactivity to Candida and PPD, the response to DNCB and the chemotaxis and NBT-dye reduction capacity of neutrophil leucocytes. The survival time of patients treated with the combination therapy was found to be significantly shorter than that of untreated patients and of those receiving cyclophosphamide only. Severe side effects were observed after C. parvum infusions, with no decrease on repeated administration. The effect of C. parvum on the different immune parameters of cyclophosphamide-treated patients was negligible, though there was a normal antibody response to C. parvum.

Full text

PDF
609

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cheema A. R., Hersh E. M. Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer. 1971 Oct;28(4):851–855. doi: 10.1002/1097-0142(1971)28:4<851::aid-cncr2820280408>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  2. Currie G. A. Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas. Br Med J. 1970 Feb 28;1(5695):541–544. doi: 10.1136/bmj.1.5695.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dellon A. L., Potvin C., Chretien P. B. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment. Cancer. 1975 Mar;35(3):687–694. doi: 10.1002/1097-0142(197503)35:3<687::aid-cncr2820350322>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  4. Drexhage H. A., van der Gaag R. D., Namavar F. Nitroblue tetrazolium-dye reduction by rat peritoneal macrophages during the uptake of Diplococcus pneumoniae, type VI. Antonie Van Leeuwenhoek. 1978;44(3-4):377–389. doi: 10.1007/BF00394314. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Rubin H., Sartiano G., Ennis L., Wolmark N. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer. 1976 Jul;38(1):119–130. doi: 10.1002/1097-0142(197607)38:1<119::aid-cncr2820380121>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  6. Fisher B., Wolmark N., Rubin H., Saffer E. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. J Natl Cancer Inst. 1975 Nov;55(5):1147–1153. doi: 10.1093/jnci/55.5.1147. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Wolmark N., Saffer E., Fisher E. R. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors. Cancer. 1975 Jan;35(1):134–143. doi: 10.1002/1097-0142(197501)35:1<134::aid-cncr2820350119>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  8. Haskell C. M. Immunologic aspects of cancer chemotherapy. Annu Rev Pharmacol Toxicol. 1977;17:179–195. doi: 10.1146/annurev.pa.17.040177.001143. [DOI] [PubMed] [Google Scholar]
  9. Lung cancer: perspectives and prospects. Ann Intern Med. 1970 Dec;73(6):1003–1024. doi: 10.7326/0003-4819-73-6-1003. [DOI] [PubMed] [Google Scholar]
  10. Middelkoop O. P., Veldhuizen R. W., Scheper R. J. E and EAC rosette-forming cells in healthy donors and cancer patients. Int Arch Allergy Appl Immunol. 1976;52(1-4):412–416. doi: 10.1159/000231708. [DOI] [PubMed] [Google Scholar]
  11. Minton J. P., Rossio J. L., Dixon B., Dodd M. C. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer. Clin Exp Immunol. 1976 Jun;24(3):441–447. [PMC free article] [PubMed] [Google Scholar]
  12. Thatcher N., Swindell R., Crowther D. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. Clin Exp Immunol. 1979 Jan;35(1):36–44. [PMC free article] [PubMed] [Google Scholar]
  13. Turk J. L., Polak L., Parker D. Control mechanisms in delayed-type hypersensitivity. Br Med Bull. 1976 May;32(2):165–170. doi: 10.1093/oxfordjournals.bmb.a071350. [DOI] [PubMed] [Google Scholar]
  14. Weening R. S., Roos D., Loos J. A. Oxygen consumption of phagocytizing cells in human leukocyte and granulocyte preparations: a comparative study. J Lab Clin Med. 1974 Apr;83(4):570–577. [PubMed] [Google Scholar]
  15. Zigmond S. H., Hirsch J. G. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973 Feb 1;137(2):387–410. doi: 10.1084/jem.137.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. al-Sarraf M., Sardesai S., Vaitkevicius V. K. Clinical immunologic responsiveness in malignant disease. II. In vitro lymphocyte response to phytohemagglutinin and the effect of cytotoxic drugs. Oncology. 1972;26(4):357–368. doi: 10.1159/000224687. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES